Effects of Rimonabant on Metabolic Risk Factors in Overweight Patients with Dyslipidemia

Cited by (999)

Items 301–400 of 999

1. Polymorphisms of Serotonin Receptor 2A and 2C Genes and COMT in Relation to Obesity and Type 2 Diabetes
   Sofia I. Iqbal Kring, Thomas Mears Werge, Claus Holst, Søren Toubro, Arne Vernon Astrup, Torben F. Hansen, Oluf Borbye Pedersen, Thorkild I. A. Sørensen · 2009 · PLoS ONE
2. Mediterranean diet and the metabolic syndrome
   Katherine Esposito, Miryam Ciotola, Dario Giugliano · 2007 · Molecular Nutrition & Food Research
3. The cDNA 385C to A missense polymorphism of the endocannabinoid degrading enzyme fatty acid amide hydrolase (FAAH) is associated with overweight/obesity but not with binge eating disorder in overweight/obese women
   Palmiero Monteleone, Alfonso Antonio Vincenzo Tortorella, Vassilis Martiadis, Carmela Di Filippo, Benedetta Canestrelli, Mario Maj · 2008 · Psychoneuroendocrinology
4. Regulation and possible role of endocannabinoids and related mediators in hypercholesterolemic mice with atherosclerosis
   Fabrizio Montecucco, Isabel Matias, Sébastien Lenglet, Stefania Petrosino, Fabienne Burger, Graziano Pelli, Vincent Braunersreuther, François Mach, Sabine Steffens, Vincenzo Di Marzo · 2009 · Atherosclerosis
5. Cannabinoid receptor 1 mediates palmitic acid‐induced apoptosis via endoplasmic reticulum stress in human renal proximal tubular cells
   Jae Cheong Lim, Seul Ki Lim, Ho Jae Han, Sungbeen Park · 2010 · Journal of Cellular Physiology
6. Weight Management for Type 2 Diabetes Mellitus: Global Cardiovascular Risk Reduction
   Michelle Lee, Louis J. Aronne · 2006 · The American Journal of Cardiology
7. Cannabinoid Receptor 2 as Antiobesity Target: Inflammation, Fat Storage, and Browning Modulation
   Francesca Rossi, Giulia Bellini, Livio Luongo, Iolanda Manzo, Salvatore Tolone, Chiara Tortora, Maria Ester Bernardo, Anna Grandone, Antonella Conforti, Ludovico Docimo et al. · 2016 · The Journal of Clinical Endocrinology & Metabolism
8. Dietary DHA reduces downstream endocannabinoid and inflammatory gene expression and epididymal fat mass while improving aspects of glucose use in muscle in C57BL/6J mice
   J Kim, Morgan E. Carlson, George A. Kuchel, John W. I. Newman, Bruce A. Watkins · 2015 · International Journal of Obesity
9. Treating the metabolic syndrome
   Cristina Bianchi, Giuseppe Penno, Fabiola Romero, Stefano Del Prato, Roberto Miccoli · 2007 · Expert Review of Cardiovascular Therapy
10. Metabolite profiling identifies anandamide as a biomarker of nonalcoholic steatohepatitis
    William Taylor Kimberly, John O’Sullivan, Anjali K. Nath, Michelle J. Keyes, Xu Dong Shi, Martin G. Larson, Qiong Yang, Michelle T. Long, Ramachandran Srini Vasan, Randall Theodore Peterson et al. · 2017 · JCI Insight
11. Trial of prevention and reduction of obesity through active living in clinical settings: a randomized controlled trial.
    R. Ross, Miu Y. Lam, S. Blair, T. Church, M. Godwin, S. Hotz, Anastasia Y. Johnson, P. Katzmarzyk, Lucie Lévesque, S. Macdonald · 2012 · Archives of Internal Medicine
12. Endocannabinoids and Liver Disease. II. Endocannabinoids in the pathogenesis and treatment of liver fibrosis
    Sören Siegmund, Robert F. Schwabe · 2007 · American Journal of Physiology-Gastrointestinal and Liver Physiology
13. Enhancement of endocannabinoid signaling and the pharmacotherapy of depression
    Regina A. Mangieri, Daniele Piomelli · 2007 · Pharmacological Research
14. Regulatory challenges for new drugs to treat obesity and comorbid metabolic disorders
    Heal, David J., Gosden, Jane, Smith, Sharon L. · 2009 · British Journal of Clinical Pharmacology
15. Long-term effects of weight-reducing drugs in people with hypertension
    Siebenhofer, Andrea, Winterholer, Sebastian, Jeitler, Klaus, Horvath, Karl, Berghold, Andrea, Krenn, Cornelia, Semlitsch, Thomas · 2021 · Cochrane Database of Systematic Reviews
16. A randomized controlled trial of adding the nicotine patch to rimonabant for smoking cessation: efficacy, safety and weight gain
    Nancy A. Rigotti, David H. Gonzales, Lowell C. Dale, Daniel L. Lawrence, Yuchiao Chang · 2009 · Addiction
17. Effect of rimonabant on blood pressure in overweight/obese patients with/without co-morbidities: analysis of pooled RIO study results
    Luis Miguel Ruilope, Jean‐Pierre Després, André Jacques Scheen, Xavier Pi‐Sunyer, Guiseppe Mancia, Alberto Zanchetti, Luc Van Gaal · 2008 · Journal of Hypertension
18. The Role of the Endocannabinoid System in Atherosclerosis
    François Mach, Sabine Steffens · 2008 · Journal of Neuroendocrinology
19. Recent advances in the management of type 2 diabetes mellitus: a review
    B. T. Srinivasan, Janet Jarvis, Kamlesh Khunti, Melanie Jane Davies · 2008 · Postgraduate Medical Journal
20. The novel cannabinoid CB1 antagonist AM6545 suppresses food intake and food-reinforced behavior
    Patrick A. Randall, Kiran V. Vemuri, Kristen N. Segovia, E. Ferreris Torres, Seth Hosmer, Eric J. Nunes, Jessica L. Santerre, Alexandros Makriyannis, John D. Salamone · 2010 · Pharmacology Biochemistry and Behavior
21. CB1 receptor blockade and its impact on cardiometabolic risk factors: overview of the RIO programme with rimonabant.
    Scheen, A. J. · 2008 · Journal of Neuroendocrinology
22. A clinical trial assessing the safety and efficacy of the CB1R inverse agonist taranabant in obese and overweight patients: low-dose study
    Joseph Proietto, A Rissanen, Joyce B. Harp, Ngozi Erondu, Qinfen Yu, S Suryawanshi, M E Jones, Amy O. Johnson‐Levonas, Steven B. Heymsfield, Keith D. Kaufman et al. · 2010 · International Journal of Obesity
23. Prävention und Therapie der Adipositas
    Hans Hauner, A. Moss, Aloys Berg, S. Bischoff, Mario Colombo‐Benkmann, Thomas Ellrott, Ute Kanthak, Detlef Kunze, Norbert Stefan, Martin Teufel et al. · 2015 · Diabetologie und Stoffwechsel
24. The Metabolic Syndrome: Definitions, Prevalence and Management
    J Levesque, Benoı̂t Lamarche · 2008 · Lifestyle Genomics
25. Damage-associated molecular patterns and their pathological relevance in diabetes mellitus
    Jung Jae Shin, Eun Kyung Lee, Tae Joo Park, Wook Kim · 2015 · Ageing Research Reviews
26. Mechanisms of Disease: HDL metabolism as a target for novel therapies
    Daniel James Rader · 2007 · Nature Clinical Practice Cardiovascular Medicine
27. Effects of Rimonabant (SR141716) on Fasting-Induced Hypothalamic-Pituitary-Adrenal Axis and Neuronal Activation in Lean and Obese Zucker Rats
    Christian Doyon, R Denis, Elena‐Dana Baraboi, Pierre Samson, Josée Lalonde, Yves Deshaies, Denis Richard · 2006 · Diabetes
28. Detailed characterization of the endocannabinoid system in human macrophages and foam cells, and anti-inflammatory role of type-2 cannabinoid receptor
    Valerio Chiurchiù, Mirko Lanuti, Giuseppina Catanzaro, Filomena Fezza, Cinzia Rapino, Mauro Maccarrone · 2014 · Atherosclerosis
29. Effect of Marked Weight Loss on Adiponectin Gene Expression and Plasma Concentrations
    Carrie C. Coughlin, Brian N. Finck, J. Christopher Eagon, Valerie J. Halpin, Faidon Magkos, B. Selma Mohammed, Samuel Klein · 2007 · Obesity
30. Gastrointestinal Regulation of Food Intake: General Aspects and Focus on Anandamide and Oleoylethanolamide
    Raffaele Capasso, Angelo Antonio Izzo · 2008 · Journal of Neuroendocrinology
31. Monounsaturated fatty acids generated via stearoyl CoA desaturase-1 are endogenous inhibitors of fatty acid amide hydrolase
    Jie Liu, Reşat Çınar, Keming Xiong, Grzegorz Godlewski, Tony Jourdan, Yuhong Lin, James Mukasa Ntambi, George Kunos · 2013 · Proceedings of the National Academy of Sciences
32. Cannabinoid Receptor 1 in the Vagus Nerve Is Dispensable for Body Weight Homeostasis But Required for Normal Gastrointestinal Motility
    Claudia R. Vianna, José Donato, Jari Rossi, Michael M. Scott, Kyriakos D. Economides, Lauren Gautron, S. Pierpont, Carol Fuzeti Elias, Joel Keith Elmquist · 2012 · Journal of Neuroscience
33. Relationship of Type 1 Cannabinoid Receptor Availability in the Human Brain to Novelty-Seeking Temperament
    Koen Van Laere, Karolien E. Goffin, Guy M Bormans, Cindy Casteels, Luc Mortelmans, J. N. J. M. De Hoon, Igor D. Grachev, Mathieu Vandenbulcke, Guido Pieters · 2009 · Archives of General Psychiatry
34. High Fat Diet Increases Circulating Endocannabinoids Accompanied by Increased Synthesis Enzymes in Adipose Tissue
    Eline N. Kuipers, Vasudev Kantae, Boukje C. Eveleens Maarse, Susan M. van den Berg, Robin van Eenige, Kimberly J. Nahon, Anne E. Reifel-Miller, Tamer Coşkun, Menno P.J. de Winther, Esther Lutgens et al. · 2019 · Frontiers in Physiology
35. Central and Peripheral Cannabinoid Receptors as Therapeutic Targets in the Control of Food Intake and Body Weight
    Stefan Engeli · 2011 · Handbook of experimental pharmacology
36. Cost-Utility Analysis of Rimonabant in the Treatment of Obesity
    Christian Hampp, Abraham G. Hartzema, Teresa L. Kauf · 2008 · Value in Health
37. Cannabinoid Type 1 Receptor: Another Arrow in the Adipocytes’ Bow
    Luigi Bellocchio, Cristina Cervino, Valentina Vicennati, Riccardo Pasquali, Uberto Pagotto · 2008 · Journal of Neuroendocrinology
38. Food Intake‐independent Effects of CB1 Antagonism on Glucose and Lipid Metabolism
    Daniela Cota, Darleen A. Sandoval, Massimiliano Olivieri, Elena Prodi, David A. D’Alessio, Stephen C. Woods, Randy J. Seeley, Silvana Obici · 2009 · Obesity
39. Review Paper: Current Strategies in the Development of Anti-obesity Drugs and Their Safety Concerns
    Chandikumar S. Elangbam · 2008 · Veterinary Pathology
40. The therapeutic potential of targeting the peripheral endocannabinoid/CB 1 receptor system
    Joseph Tam, Liad Hinden, Adi Drori, Shiran Udi, Shahar Azar, Saja Baraghithy · 2018 · European Journal of Internal Medicine
41. Rimonabant
    Sheridan Henness, Dean M Robinson, Katherine Ann Lyseng-Williamson · 2006 · Drugs
42. Metabolic Syndrome
    Lionel Henry Opie · 2007 · Circulation
43. Functional Selectivity of a Biased Cannabinoid-1 Receptor (CB 1 R) Antagonist
    Ziyi Liu, Malliga R. Iyer, Grzegorz Godlewski, Tony Jourdan, Jie Liu, Nathan J. Coffey, Charles N. Zawatsky, Henry L. Puhl, Jürgen Wess, Jaroslawna Meister et al. · 2021 · ACS Pharmacology & Translational Science
44. Randomized Controlled Trials of the D1/D5 Antagonist Ecopipam for Weight Loss in Obese Subjects
    Arne Vernon Astrup, Frank L. Greenway, Walter W Ling, Lisa D. Pedicone, Jean E. Lachowicz, Catherine D. Strader, Rudolf Kwan, Ecopipam Obesity Study Group · 2007 · Obesity
45. Suppression by the cannabinoid CB1 receptor antagonist, rimonabant, of the reinforcing and motivational properties of a chocolate-flavoured beverage in rats
    Paola Maccioni, Daniela Pes, Mauro A.M. Carai, Gian Luigi Gessa, Giancarlo Colombo · 2008 · Behavioural Pharmacology
46. Antagonism of peripheral hepatic cannabinoid receptor-1 improves liver lipid metabolism in mice: Evidence from cultured explants
    Tony Jourdan, Laurent Demizieux, Joseph Gresti, Louiza Djaouti, Lila Gaba, Bruno L Vergès, Pascal Degrace · 2011 · Hepatology
47. Appetite Suppressants, Cardiac Valve Disease and Combination Pharmacotherapy
    Richard B. Rothman, Michael H. Baumann · 2008 · American Journal of Therapeutics
48. Some effects of CB1 antagonists with inverse agonist and neutral biochemical properties
    Jack Bergman, Marcus Sherode Delatte, Carol Anne Paronis, Kiran V. Vemuri, Ganesh A. Thakur, Alexandros Makriyannis · 2007 · Physiology & Behavior
49. Role of activated endocannabinoid system in regulation of cellular cholesterol metabolism in macrophages
    Li Jiang, Jun Pu, Z.-h. Han, L.-h. Hu, Ben He · 2008 · Cardiovascular Research
50. A Review of Weight Loss Following Roux-en-Y Gastric Bypass vs Restrictive Bariatric Surgery: Impact on Adiponectin and Insulin
    Butner, Katrina L., Nickols-Richardson, Sharon M., Clark, Susan F., Ramp, Warren K., Herbert, William G. · 2010 · Obesity Surgery
51. CB 1receptor antagonists: new discoveries leading to new perspectives
    Eszter Kirilly, Xénia Gonda, György Bagdy · 2011 · Acta Physiologica
52. What is the prognosis for new centrally-acting anti-obesity drugs?
    David J. Heal, Jane Gosden, Sharon L. Smith · 2012 · Neuropharmacology
53. Cannabinoid Receptor Type 1 (CB1R) Signaling Regulates Hepatic Gluconeogenesis via Induction of Endoplasmic Reticulum-bound Transcription Factor cAMP-responsive Element-binding Protein H (CREBH) in Primary Hepatocytes
    Dipanjan Chanda, Don‐Kyu Kim, Tiangang Li, Yong‐Hoon Kim, Seung‐Hoi Koo, Chul‐Ho Lee, John Y.L. Chiang, Hueng‐Sik Choi · 2011 · Journal of Biological Chemistry
54. Metabolic syndrome: Clinical concept and molecular basis
    Tohru Funahashi, Yūji Matsuzawa · 2007 · Annals of Medicine
55. Potential antipsychotic properties of central cannabinoid (CB1) receptor antagonists
    Patrik Roser, Franz X. Vollenweider, Wolfram Kawohl · 2008 · The World Journal of Biological Psychiatry
56. Validity of a new automated software program for visceral adipose tissue estimation
    Ellen W. Demerath, K J Ritter, William P. Couch, N L Rogers, Gabriel Jacob Moreno, Audrey C. Choh, M Lee, Karen E. Remsberg, S. Czerwiński, W. C. Chumlea et al. · 2006 · International Journal of Obesity
57. The Endocannabinoid System and Heart Disease: The Role of Cannabinoid Receptor Type 2
    Makenzie L. Fulmer, Douglas P. Thewke · 2018 · Cardiovascular & Haematological Disorders - Drug Targets
58. Cannabinoid-sensitive receptors in cardiac physiology and ischaemia
    Sarah‐Lena Puhl · 2019 · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research
59. Rimonabant: A novel selective cannabinoid-1 receptor antagonist for treatment of obesity
    Priti N. Patel, Rolee Pathak · 2007 · American Journal of Health-System Pharmacy
60. Rimonabant: a selective blocker of the cannabinoid CB1 receptors for the management of obesity, smoking cessation and cardiometabolic risk factors
    Eli V. Gelfand, Christopher Paul Cannon · 2006 · Expert Opinion on Investigational Drugs
61. Safety of obesity drugs
    Frank L. Greenway, Mary Katherine Caruso · 2005 · Expert Opinion on Drug Safety
62. Strategies for preventing type 2 diabetes: an update for clinicians
    Kaivan Khavandi, Halima Amer, Bashar Ibrahim, Jack R W Brownrigg · 2013 · Therapeutic Advances in Chronic Disease
63. Progress in the treatment of type 2 diabetes: new pharmacologic approaches to improve glycemic control
    Allison Cohen, Edward S. Horton · 2007 · Current Medical Research and Opinion
64. Adiponectin--an adipokine with unique metabolic properties
    A Wiecek, Marcin Adamczak, Jerzy Tadeusz Chudek · 2007 · Nephrology Dialysis Transplantation
65. Cannabinoid receptors as new targets of antifibrosing strategies during chronic liver diseases
    Ariane Mallat, Fatima Teixeira-Clerc, Vanessa Deveaux, Sophie Lotersztajn · 2007 · Expert Opinion on Therapeutic Targets
66. Effect of Fenofibrate on Adiponectin and Inflammatory Biomarkers in Metabolic Syndrome Patients
    Robert S. Rosenson · 2008 · Obesity
67. Overactive endocannabinoid signaling impairs apolipoprotein E-mediated clearance of triglyceride-rich lipoproteins
    Maxwell A. Ruby, Daniel K. Nomura, Carolyn S. S. Hudak, Lara M. Mangravite, Sally Chiu, John E. Casida, Ronald M. Krauss · 2008 · Proceedings of the National Academy of Sciences
68. The endocannabinoid system: Role in glucose and energy metabolism
    Rubén Nogueiras, Adenis Díaz–Arteaga, Sarah Haas Lockie, D Velasquez, Johannes Tschöp, Miguel López, Charles C. Cadwell, Carlos Diéguez, Matthias H. Tschöp · 2009 · Pharmacological Research
69. Regulation of lipid metabolism by energy availability: a role for the central nervous system
    Rubén Nogueiras, Miguel López, Carlos Diéguez · 2009 · Obesity Reviews
70. Effect of rimonabant on carotid intima–media thickness (CIMT) progression in patients with abdominal obesity and metabolic syndrome: the AUDITOR Trial
    Daniel H. O’Leary, Anne Q. Reuwer, Steven E. Nissen, Jean‐Pierre Després, John Eric Deanfield, Michael W Brown, Rong Zhou, S. Zabbatino, Bernard Job, John J.P. Kastelein et al. · 2011 · Heart
71. Endocannabinoids and related N-acylethanolamines in the control of appetite and energy metabolism: emergence of new molecular players
    Didier M. Lambert, Giulio G. Muccioli · 2007 · Current Opinion in Clinical Nutrition & Metabolic Care
72. Effect of the cannabinoid CB1receptor antagonist rimonabant on nociceptive responses and adjuvant‐induced arthritis in obese and lean rats
    Tiziano Croci, Elena Zarini · 2007 · British Journal of Pharmacology
73. Cardiovascular risk in South Asians
    Radhakrishnan Ramaraj, Parkavi Chellappa · 2008 · Postgraduate Medical Journal
74. A Preliminary Investigation of α-Lipoic Acid Treatment of Antipsychotic Drug-Induced Weight Gain in Patients With Schizophrenia
    Eosu Kim, Dong-Wha Park, Song-Hee Choi, Jae‐Jin Kim, Hyun-Sang Cho · 2008 · Journal of Clinical Psychopharmacology
75. Overweight and obesity: Key components of cardiometabolic risk
    Louis J. Aronne, Kathy K. Isoldi · 2007 · Clinical cornerstone
76. Differential effects of CB1 neutral antagonists and inverse agonists on gastrointestinal motility in mice
    Martin Storr, Mohammad Bashashati, Christina L. Hirota, Kiran V. Vemuri, Catherine M. Keenan, Marnie Duncan, Beat Lutz, Ken Mackie, Alexandros Makriyannis, Wallace Keith MacNaughton et al. · 2010 · Neurogastroenterology & Motility
77. Metabolic complications of obesity: inflated or inflamed?
    Manisha Chandalia, Nicola I. Abate · 2007 · Journal of Diabetes and its Complications
78. The Clinical Implications of Blood Adiponectin in Cardiometabolic Disorders
    Lin‐Chau Chang, Kuo‐Chin Huang, Yen‐Wen Wu, Hsien‐Li Kao, Chi‐Ling Chen, Ling‐Ping Lai, Juey‐Jen Hwang, Wei‐Shiung Yang · 2009 · Journal of the Formosan Medical Association
79. Primary Prevention of Cardiovascular Disease in People With Dysglycemia
    Cristina Bianchi, Roberto Miccoli, Giuseppe Penno, Stefano Del Prato · 2008 · Diabetes Care
80. Hepatitis C Virus Induces the Cannabinoid Receptor 1
    David van der Poorten, Mahsa Shahidi, Enoch S. E. Tay, Jayshree Sesha, Kayla L. Tran, Duncan J. McLeod, Jane S. Milliken, Vikki Ho, Lionel Hebbard, Mark W. Douglas et al. · 2010 · PLoS ONE
81. Obesity and type 2 diabetes
    Subhashini Yaturu · 2011 · Journal of Diabetes Mellitus
82. The potential use of selective 5-HT2Cagonists in treating obesity
    Brian M Smith, William J. Thomsen, Andrew J. Grottick · 2006 · Expert Opinion on Investigational Drugs
83. Regulation of the Hypothalamic-Pituitary-Adrenal Axis Circadian Rhythm by Endocannabinoids Is Sexually Diergic
    Helen C. Atkinson, James D. Leggett, Susan A. Wood, Emma S. Castrique, Yvonne M. Kershaw, Stafford Louis Lightman · 2010 · Endocrinology
84. The Effects of Medications Used for the Management of Diabetes and Obesity on Postprandial Lipid Metabolism
    Eleftheriadou, Ioanna, Grigoropoulou, Pinelopi, Katsilambros, Nicholas, Tentolouris, Nicholas · 2008 · Current Diabetes Reviews
85. A one‐year study to assess the safety and efficacy of the CB1R inverse agonist taranabant in overweight and obese patients with type 2 diabetes
    Mark S. Kipnes, Priscilla A. Hollander, Ken Fujioka, Ira Gantz, Thomas L. Seck, Ngozi Erondu, Yue Shentu, Kaifeng Lu, S Suryawanshi, Margaret Z. Chou et al. · 2009 · Diabetes Obesity and Metabolism
86. Endocannabinoid regulation of β ‐cell functions: implications for glycaemic control and diabetes
    Tony Jourdan, Grzegorz Godlewski, George Kunos · 2016 · Diabetes Obesity and Metabolism
87. WIN55,212-2-Mediated Inhibition of HIV-1 Expression in Microglial Cells: Involvement of Cannabinoid Receptors
    Robert Bryan Rock, Genya Gekker, Shuxian Hu, Wen S. Sheng, Guy A. Cabral, Billy R. Martin, Phillip K. Peterson · 2006 · Journal of Neuroimmune Pharmacology
88. Endocannabinoids, Adipose Tissue and Lipid Metabolism
    Claudio Pagano, Marco Rossato, Roberto Vettor · 2008 · Journal of Neuroendocrinology
89. Endocannabinoids and Their Receptors as Targets for Obesity Therapy
    Annette D. de Kloet, Stephen C. Woods · 2009 · Endocrinology
90. Use of cannabinoid CB1 receptor antagonists for the treatment of metabolic disorders
    André Jacques Scheen, Nicolas Paquot · 2009 · Best Practice & Research Clinical Endocrinology & Metabolism
91. Feeding Behavior in Mammals Including Humans
    Paolo Magni, Elena Dozio, Massimiliano Ruscica, Fabio Celotti, Maria Angela Masini, Paola Prato, Marco Broccoli, Andrea Mambro, Massimo Morè, Felice Strollo · 2009 · Annals of the New York Academy of Sciences
92. Pharmacotherapy for Obesity — Promise and Uncertainty
    Susan Zelitch Yanovski · 2005 · New England Journal of Medicine
93. Role of adiponectin in the metabolic effects of cannabinoid type 1 receptor blockade in mice with diet-induced obesity
    Joseph Tam, Grzegorz Godlewski, Brian James Earley, Liang Zhou, Tony Jourdan, Gergő Szanda, Reşat Çınar, George Kunos · 2014 · American Journal of Physiology-Endocrinology and Metabolism
94. Rimonabant, a Cannabinoid Receptor Type 1 Inverse Agonist, Inhibits Hepatocyte Lipogenesis by Activating Liver Kinase B1 and AMP-Activated Protein Kinase Axis Downstream of Gαi/o Inhibition
    Hongmin Wu, Yoon Mee Yang, Sang Geon Kim · 2011 · Molecular Pharmacology
95. Rimonabant ameliorates insulin resistance via both adiponectin-dependent and adiponectin-independent pathways
    Watanabe, Taku, Kubota, Naoto, Ohsugi, Mitsuru, Kubota, Tetsuya, Takamoto, Iseki, Iwabu, Masato, Awazawa, Motoharu, Katsuyama, Hisayuki, Hasegawa, Chiaki, Tokuyama, Kumpei et al. · 2009 · Journal of Biological Chemistry
96. Pharmacological and non-pharmacological interventions to influence adipose tissue function
    Jan Westerink, Frank L.J. Visseren · 2011 · Cardiovascular Diabetology
97. Grooming, scratching and feeding: role of response competition in acute anorectic response to rimonabant in male rats
    A.J. Tallett, John Edward Blundell, R. John Rodgers · 2007 · Psychopharmacology
98. Effect of DHA supplementation in a very low-calorie ketogenic diet in the treatment of obesity: a randomized clinical trial
    Daniel Antonio de Luis, Joan Carles Domingo, Olatz Izaola, Felipe F. Casanueva, Diego Bellido, Ignacio Sajoux · 2016 · Endocrine
99. Role of the Endocannabinoid System in the Adipose Tissue with Focus on Energy Metabolism
    Volatiana Rakotoarivelo, Jyoti Sihag, Nicolas Flamand · 2021 · Cells
100. Cannabinoid receptors as therapeutic targets for obesity and metabolic diseases
     Luigi Bellocchio, G MANCINI, Valentina Vicennati, Riccardo Pasquali, Uberto Pagotto · 2006 · Current Opinion in Pharmacology